Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

OCS

Oculis Holding AG

May 24 • 04:00PM ET

11.85

Dollar change -0.05
Percentage change -0.42	%

Healthcare • Biotechnology • Switzerland • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: SMLV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.86	Insider Own	45.78%	Shs Outstand	36.65M	Perf Week	-1.04%
Market Cap	435.37M	Forward P/E	-	EPS next Y	-2.16	Insider Trans	0.00%	Shs Float	19.92M	Perf Month	-0.84%
Income	-66.53M	PEG	-	EPS next Q	-0.45	Inst Own	3.81%	Short Float	0.23%	Perf Quarter	-5.43%
Sales	0.00M	P/S	-	EPS this Y	-3.61%	Inst Trans	4.32%	Short Ratio	1.16	Perf Half Y	20.37%
Book/sh	2.39	P/B	4.95	EPS next Y	-16.17%	ROA	-	Short Interest	0.05M	Perf Year	-4.66%
Cash/sh	2.42	P/C	4.91	EPS next 5Y	31.49%	ROE	-	52W Range	9.05 - 14.50	Perf YTD	5.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-75.43%	52W High	-18.28%	Beta	0.09
Dividend TTM	-	Quick Ratio	4.71	Sales past 5Y	0.00%	Gross Margin	-	52W Low	30.94%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	4.71	EPS Y/Y TTM	-2146.64%	Oper. Margin	0.00%	RSI (14)	42.54	Volatility	0.81% 2.17%
Employees	36	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.38	Target Price	28.09
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-	Payout	-	Rel Volume	0.03	Prev Close	11.90
Sales Surprise	-14.46%	EPS Surprise	-17.01%	Sales Q/Q	-	Earnings	May 08 AMC	Avg Volume	39.76K	Price	11.85
SMA20	-3.67%	SMA50	-0.55%	SMA200	2.19%	Trades		Volume	1,028	Change	-0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-23	Initiated	Chardan Capital Markets	Buy	$30
Oct-05-23	Initiated	Stifel	Buy	$35
Jun-14-23	Initiated	BofA Securities	Buy	$22
Jun-12-23	Initiated	H.C. Wainwright	Buy	$28
Jun-08-23	Initiated	Robert W. Baird	Outperform	$58
May-10-23	Initiated	Pareto	Buy	$23
Apr-28-23	Initiated	Wedbush	Outperform	$27

May-18-24 09:07AM	OCS Stock Earnings: Oculis Holding Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-17-24 04:30PM	Oculis updates share capital for its existing at-the-market offering program (GlobeNewswire)
May-08-24 04:10PM	Oculis Reports Q1 2024 Financial Results and Provides Company Updates (GlobeNewswire)
04:05PM	Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis (GlobeNewswire)
May-07-24 04:05PM	Oculis Publishes Invitation to the Annual General Meeting (GlobeNewswire)
06:30AM	Loading…
May-06-24 06:30AM	Oculis to Present at Bank of America Global Healthcare Conference (GlobeNewswire)
Apr-29-24 04:05PM	Oculis Publishes Invitation to the Annual General Meeting (GlobeNewswire) +5.91%
Apr-22-24 09:27AM	Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market (GlobeNewswire)
Apr-11-24 08:55AM	Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market (GlobeNewswire)
Apr-10-24 06:30AM	Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development (GlobeNewswire) +6.18%
Apr-08-24 06:30AM	Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting (GlobeNewswire)
Apr-04-24 06:30AM	Oculis to Participate at Upcoming April Investor Conferences (GlobeNewswire)
Mar-18-24 06:30AM	Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress (GlobeNewswire)
Feb-28-24 06:30AM	Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments (GlobeNewswire)
Feb-01-24 09:55AM	How Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77% (Zacks)
08:50AM	Loading…
Jan-29-24 08:50AM	What Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing' (Zacks)
06:30AM	Oculis to Present at Upcoming February Investor Conferences (GlobeNewswire)
Jan-22-24 06:30AM	Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024 (GlobeNewswire)
Jan-16-24 09:55AM	Can Oculis Holding AG (OCS) Climb 191.31% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-20-23 06:30AM	Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery (GlobeNewswire)
Dec-18-23 06:30AM	Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema (GlobeNewswire)
Dec-07-23 06:30AM	Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF Licaminlimab (OCS-02) in Dry Eye Disease (GlobeNewswire)
Nov-15-23 06:30AM	Oculis Reports Q3 2023 Financial Results and Provides Company Update (GlobeNewswire)
Nov-08-23 06:30AM	Oculis to Present at Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-23 06:30AM	Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema (GlobeNewswire) -7.14%
Oct-10-23 06:30AM	Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress (GlobeNewswire)
Oct-05-23 06:30AM	Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema (GlobeNewswire)
Sep-11-23 06:30AM	Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase (GlobeNewswire)
Aug-30-23 06:30AM	Oculis to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-29-23 06:30AM	Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update (GlobeNewswire)
06:30AM	Loading…
Aug-08-23 06:30AM	OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery (GlobeNewswire)
Aug-02-23 08:00AM	First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema (GlobeNewswire)
Jul-26-23 08:00AM	Oculis Announces to Present at Upcoming August Investor Conferences (GlobeNewswire)
Jul-19-23 08:00AM	Oculis to Present at OIS Retina Innovation Summit (GlobeNewswire)
Jun-26-23 08:00AM	Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023 (GlobeNewswire)
Jun-13-23 04:01PM	Oculis Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares (GlobeNewswire)
Jun-12-23 08:00AM	Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile)
08:00AM	Oculis to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 11:59PM	Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares (GlobeNewswire)
May-30-23 07:06AM	Oculis Announces Launch of Proposed Public Offering of Ordinary Shares (GlobeNewswire) -7.75%
May-24-23 08:00AM	Oculis to Participate and Present at Upcoming EuDES Meeting (GlobeNewswire)
May-22-23 06:30AM	Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops (GlobeNewswire) +5.29%
May-11-23 08:00AM	Oculis Co-founders Selected as Finalists in European Inventor Award 2023 (GlobeNewswire)
Apr-26-23 07:00AM	Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Apr-05-23 07:00AM	Oculis to Participate at Upcoming Investor Conferences (GlobeNewswire)
Apr-04-23 07:00AM	Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones (GlobeNewswire)
Mar-22-23 07:00AM	Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing (GlobeNewswire) -7.01%
Mar-16-23 09:45AM	Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial (GlobeNewswire)

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCS

Oculis Holding AG

Upgrade your FINVIZ experience